-
Mashup Score: 0Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease - 30 day(s) ago
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic. Subcutaneous Entyvio (vedolizumab, Takeda Pharmaceuticals) was previously approved in 2023 for moderate-to-severe ulcerative colitis. The company noted
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
❗️@TakedaPharma's subcutaneous #vedolizumab picks up second #FDA approval for moderate-to-severe #Crohns disease ❗️ 🔎VISIBLE 2 data found that “half of patients treated with subcutaneous #Entyvio achieved long-term clinical remission...” https://t.co/ZPKFj4uvW9